$NGNE
Neurogene Inc. Stock $ngne

$ngne Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514395314 Filed on November 04, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.490M	$990.0K	$690.0K
YoY Change	115.94%	153.85%	25.45%
% of Gross Profit
Research & Development	$6.330M	$5.323M	$2.750M
YoY Change	130.18%	75.84%	235.37%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$7.820M	$6.310M	$3.440M
YoY Change	127.33%	84.66%	145.71%
Operating Profit
YoY Change
Interest Expense	-$10.00K	$2.000K	-$50.00K
YoY Change	-80.0%	21.73%	400.0%
% of Operating Profit
Other Income/Expense, Net	-$260.0K	$26.00K	-$50.00K
YoY Change	420.0%	-41.62%	400.0%
Pretax Income	-$8.090M	-$6.284M	-$3.540M
YoY Change	128.53%	86.33%	147.55%
Income Tax	$0.00	-$222.00	$0.00
% Of Pretax Income
Net Earnings	-$8.090M	-$6.284M	-$3.540M
YoY Change	128.53%	86.61%	147.55%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$754.7K	-$586.9K	-$11.80M
COMMON SHARES
Basic Shares Outstanding	10.70M shares	10.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.10M	$40.00M	$13.80M
YoY Change	183.33%	151.57%	590.0%
Cash & Equivalents	$14.91M	$15.87M	$11.01M
Short-Term Investments	$24.20M	$24.10M	$2.800M
Other Short-Term Assets	$100.0K	$300.0K	$1.500M
YoY Change	-93.33%	200.0%
Inventory
Prepaid Expenses		$283.9K	$63.98K
Receivables	$100.0K	$100.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$39.30M	$40.36M	$15.30M
YoY Change	156.93%	152.27%	628.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$105.0K	$97.58K	$75.47K
YoY Change	39.14%	-2.42%	-62.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$8.100M
YoY Change
Other Assets	$13.00K	$13.86K	$277.3K
YoY Change	-95.31%	-86.14%
Total Long-Term Assets	$2.121M	$8.251M	$352.8K
YoY Change	501.27%	4025.75%	76.38%
TOTAL ASSETS
Total Short-Term Assets	$39.30M	$40.36M	$15.30M
Total Long-Term Assets	$2.121M	$8.251M	$352.8K
Total Assets	$41.42M	$48.62M	$15.65M
YoY Change	164.69%	200.09%	580.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.200M	$4.600M	$600.0K
YoY Change	766.67%	318.18%	200.0%
Accrued Expenses			$1.700M
YoY Change			1600.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$300.0K
YoY Change
Total Short-Term Liabilities	$5.203M	$4.572M	$2.620M
YoY Change	98.58%	117.7%	555.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.000M
YoY Change	-100.0%
Other Long-Term Liabilities	$72.00K	$100.0K	$8.560K
YoY Change	741.12%	-96.3%	-99.22%
Total Long-Term Liabilities	$72.00K	$100.0K	$8.560K
YoY Change	741.12%	-96.3%	-99.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.203M	$4.572M	$2.620M
Total Long-Term Liabilities	$72.00K	$100.0K	$8.560K
Total Liabilities	$5.275M	$4.635M	$7.484M
YoY Change	-29.52%	-3.43%	398.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$89.42M	-$81.33M	-$65.69M
YoY Change	36.11%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.15M	$43.98M	-$65.69M
YoY Change
Total Liabilities & Shareholders Equity	$41.42M	$48.62M	$15.65M
YoY Change	164.69%	200.09%	580.4%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$8.090M	-$6.284M	-$3.540M
YoY Change	128.53%	86.61%	147.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$6.700M	-$4.180M	-$3.740M
YoY Change	79.14%	140.23%	233.93%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$20.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$6.080M	$2.220M	-$2.810M
YoY Change	-316.37%	11000.0%
Cash From Investing Activities	$6.050M	$2.210M	-$2.810M
YoY Change	-315.3%	10950.0%	28000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-50.00K	1.800M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-6.700M	-4.180M	-3.740M
Cash From Investing Activities	6.050M	2.210M	-2.810M
Cash From Financing Activities	0.000	-50.00K	1.800M
Net Change In Cash	-650.0K	-2.020M	-4.750M
YoY Change	-86.32%	17.44%	320.35%
FREE CASH FLOW
Cash From Operating Activities	-$6.700M	-$4.180M	-$3.740M
Capital Expenditures	-$20.00K	-$20.00K	$0.00
Free Cash Flow	-$6.680M	-$4.160M	-$3.740M
YoY Change	78.61%	139.08%	236.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	1.00	pure
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10695108	shares
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	11.00
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15867885
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	0
CY2014Q3	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	0
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4571782
CY2014Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	63708
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7301
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81325064
CY2014Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent
CY2014Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4571782
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	43979878
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48615368
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125297630
CY2014Q3	us-gaap	Line Of Credit LineOfCredit	0
CY2014Q3	us-gaap	Liabilities Liabilities	4635490
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15869234
CY2014Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	32210885
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	97581
CY2014Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	8140052
CY2014Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	76243
CY2014Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11576306
CY2014Q3	us-gaap	Long Term Investments LongTermInvestments	8140052
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2024-05-07
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	175500	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.10
CY2014Q3	us-gaap	Assets Assets	48615368
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2981589
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	24134541
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19445
CY2013Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	250000
CY2013Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	2036489
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2620105
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3906	shares
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	221320
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65693708
CY2013Q2	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	5.76
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.052083	pure
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1797412
CY2014Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	24134541
CY2014Q3	us-gaap	Cash Cash	4292928
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13864
CY2014Q3	us-gaap	Assets Current AssetsCurrent	40363871
CY2014Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283853
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2000539
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	73858722
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2350660
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-65693708
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8560
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15649106
CY2013Q4	us-gaap	Line Of Credit LineOfCredit	2286489
CY2013Q4	us-gaap	Liabilities Liabilities	7484092
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11006392
CY2013Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	1799074
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75465
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	27946
CY2013Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3714276
CY2013Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1377438
CY2013Q4	us-gaap	Assets Assets	15649106
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	2820600
CY2013Q4	us-gaap	Cash Cash	7292116
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277290
CY2013Q4	us-gaap	Assets Current AssetsCurrent	15296351
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	63975
CY2013Q4	aqxp	Derivative Liabilities Noncurrent Redemption Option DerivativeLiabilitiesNoncurrentRedemptionOption	800206
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2023-05-29
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4847276
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13867346
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5044
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	96039
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17776058
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	181618
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	174385
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6510	shares
CY2013Q2	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	5.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4083097
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1085586
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2024-08-06
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.50
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2023-04-01
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	39322	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.76
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2023-04-07
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	13020	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.76
CY2014Q1	aqxp	Number Of Non Employee Directors NumberOfNonEmployeeDirectors	4	Directors
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4830000	shares
CY2014Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	5838726
CY2014Q1	aqxp	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	47291274
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2023-06-24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	301745	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-32.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.93	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6040020	shares
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	223910
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	36701
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35801
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5547
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5194300
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	124353
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5189256
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	738562
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	972757
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7233
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9660864
	us-gaap	Net Income Loss NetIncomeLoss	-5189256
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45198
	us-gaap	Interest Expense InterestExpense	5246
	us-gaap	Operating Expenses OperatingExpenses	5932862
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1678451
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	17999968
	us-gaap	Share Based Compensation ShareBasedCompensation	255318
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	265650
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	421974
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	25000
	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	3953595
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	AQUINOX PHARMACEUTICALS, INC
	dei	Trading Symbol TradingSymbol	AQXP
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.33
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M13D
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated and combined the “Company”—see Note 2 Basis of presentation) is a clinical stage pharmaceutical company discovering and developing oral drug candidates to treat inflammation and cancer. The Company’s primary focus is the development of anti-inflammatory product candidates targeting SHIP1, which is a key regulator of a cellular signaling pathway in immune cells. Aquinox Pharmaceuticals (USA) Inc. was incorporated on May 31, 2007 in the State of Delaware, United States. On January 27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (“Aquinox USA”).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”), was originally incorporated under the name of 6175813 Canada Inc. on December 26, 2003 under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company operates in Vancouver, British Columbia, Canada.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10791507
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.052083	pure
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company effected a 1-for-19.2 reverse stock split
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(b) Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates are the valuation of stock options and warrants, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7984052	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.97
	dei	Entity Central Index Key EntityCentralIndexKey	0001404644
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	824721	shares
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15936739
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5312
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15929216
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1380123
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2982940
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	53130000
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	-590
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6920438
	us-gaap	Share Based Compensation ShareBasedCompensation	585111
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36474883
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-107754
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	9844
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2609844
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4943
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	125082
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	48297
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	957818
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	7301
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5251288
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86322
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15730777
	us-gaap	Net Income Loss NetIncomeLoss	-15936517
	us-gaap	Interest Paid InterestPaid	31719
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7301
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	115490
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
	us-gaap	Interest Expense InterestExpense	458651
	us-gaap	Operating Expenses OperatingExpenses	14556616
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11753749
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	319635
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4862842
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-222
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	186356
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	19551
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	45278582
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16534
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-29624233
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	460
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2802867
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10695042	shares
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	80167
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	1884233
	aqxp	Extinguishment Of Discount On Temporary Equity ExtinguishmentOfDiscountOnTemporaryEquity	800206
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	100291
	aqxp	Reversal Of Income Tax Payable On Preferred Stock ReversalOfIncomeTaxPayableOnPreferredStock	1897702
	aqxp	Accretion Of Warrant Discount AccretionOfWarrantDiscount	213511
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170	pure
CY2013Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	9602
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	389862
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	127161
	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	1132893
	aqxp	Period Shares Reserved For Issuance Will Increase PeriodSharesReservedForIssuanceWillIncrease	P10Y
	aqxp	Fee And Penalty On Bank Loan Repayment FeeAndPenaltyOnBankLoanRepayment	100000
	aqxp	Long Term Investments Maturity Period Maximum LongTermInvestmentsMaturityPeriodMaximum	P24M
CY2013Q3	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	120762
CY2013Q3	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	-54726
CY2013Q3	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	1397867
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.16
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	aqxp	Common Stock Reserved For Issuance Description CommonStockReservedForIssuanceDescription	Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
	aqxp	Stock Based Compensation Increase In Common Stock Issuance Percentage StockBasedCompensationIncreaseInCommonStockIssuancePercentage	0.04	pure
	aqxp	Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock	439227
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2500000
CY2013	aqxp	Discount On Issuance Of Warrants DiscountOnIssuanceOfWarrants	226255
CY2013	aqxp	Accretion Of Warrant Discount1 AccretionOfWarrantDiscount1	12744
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	301745	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.64
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6040020	shares
CY2013Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	142071
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3372531
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3367487
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	44537
CY2013Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	24871
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4720230
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-3367487
CY2013Q3	us-gaap	Interest Expense InterestExpense	1643
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	3417068
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3027206
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5044
CY2014Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	86	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	824721	shares
CY2014Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1350
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6284302
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6277659
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25583
CY2014Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	29388
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6284080
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6284080
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6421
CY2014Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2014Q3	us-gaap	Interest Expense InterestExpense	2455
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	6309885
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5323015
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-222
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	986870
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	232635
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	141

Files In Submission

Name	View Source	Status
0001193125-14-395314-index-headers.html	Edgar Link	pending
0001193125-14-395314-index.html	Edgar Link	pending
0001193125-14-395314.txt	Edgar Link	pending
0001193125-14-395314-xbrl.zip	Edgar Link	pending
aqxp-20140930.xml	Edgar Link	completed
aqxp-20140930.xsd	Edgar Link	pending
aqxp-20140930_cal.xml	Edgar Link	unprocessable
aqxp-20140930_def.xml	Edgar Link	unprocessable
aqxp-20140930_lab.xml	Edgar Link	unprocessable
aqxp-20140930_pre.xml	Edgar Link	unprocessable
d796415d10q.htm	Edgar Link	pending
d796415dex101.htm	Edgar Link	pending
d796415dex311.htm	Edgar Link	pending
d796415dex312.htm	Edgar Link	pending
d796415dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NGNE
Neurogene Inc. Stock $ngne

2014 Q4 Form 10-Q Financial Statement

#000119312514395314 Filed on November 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE Neurogene Inc. Stock $ngne

2014 Q4 Form 10-Q Financial Statement

#000119312514395314 Filed on November 04, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE
Neurogene Inc. Stock $ngne